Malumbres’s group had previously discovered that the inactivation of another APC/C protein, Cdc20, prevented cell division. These results caught the attention of pharmaceutical companies, who are already developing the first inhibitors from the complex. …
A Spanish National Cancer Research Centre (CNIO) work, led by Alfonso Valencia, Vice-Director of Basic Research, and Michael L. Tress, a researcher on his team, brings together the biggest collection of interactions between pharmacological molecules, including other compounds, and proteins, in the latest edition of the journal Nucleid Acids Research…
The authors analyzed the genome of tumor cells at the onset of the disease and within several years after treatment, when the relapses occur. Thus, it has been possible to evaluate the genomic modifications associated with disease progression. These analyses have discovered the implication of several genes in the progression of these lymphomas and some mechanisms generating resistance to chemotherapy. …
A national team of researchers has analysed the risk that women diagnosed with a first case of invasive breast cancer face of developing a second primary cancer in a part of the body other than the breast. The results, published in the journal Gynecologic Oncology, indicate that this risk is 39% higher. María José Sánchez, co-author of the study and director of the Granada Cancer Register explained to SINC that the team’s study is the first populational study ever conducted in Spain to examine this associated risk. According to the study’s data, women under the age of 50 who had previously suffered from breast cancer were almost twice as likely to develop a second cancer than the general population (the risk was 96% greater). …
The Cell Division & Cancer Group, led by Spanish National Cancer Research Centre (CNIO) researcher Marcos Malumbres, has managed to decode a new mechanism that regulates cell division, in which the key molecule involved, Greatwall − also known as Mastl− could be a new therapeutic target for oncology treatments. The study is published today in the scientific journal Proceedings of the National Academy of Sciences (PNAS). GREATWALL: A KEY PLAYER OF THE CELL DIVISION PUZZLE The control of cell division or mitosis depends on many proteins, amongst them, Aurora and Polo. Currently, many pharmaceutical companies have shown interest in these molecules, for which inhibitors have already been developed, some of which are currently undergoing clinical trials in oncology…
source : http://www.foxnews.com/health/2013/07/02/healthy-and-delicious-july-4th-recipes/
Using focus groups with 36 Spanish-speaking cancer survivors from Tampa and Puerto Rico, researchers found that a language barrier, as well as a cultural idea that only doctors, not patients, guide treatment decisions, may help account for low participation rates. Looking for ways to improve knowledge and participation for Hispanic patients, the researchers used feedback from the focus groups to help develop a Spanish booklet and video to educate and empower patients to participate in treatment decisions. …
If caught early, melanoma is relatively easy to treat. But in its late stages, it is a stubborn and deadly cancer. Until about a decade ago, patients survived only about seven months after starting treatment. Since then, therapies, such as vemurafenib, that specifically target signaling proteins essential to the proliferation and survival of melanoma cells have extended the lives of some patients. …
The team led by Spanish National Cancer Research Centre researcher Óscar Fernández-Capetillo, head of the Genomic Instability Group, together with researchers from the National Cancer Institute in the US, have participated in a study that describes the causes that explain why tumours with BRCA1 and BRCA2 mutations stop responding to PARP inhibitor drugs. "PARP inhibitors are only toxic in tumours that have an impaired DNA repair mechanism, such as those that contain BRCA1/2 mutations" says María Nieto-Soler, a researcher from Fernández-Capetillo’s team…
A group from the Spanish National Cancer Research Centre (CNIO), headed by researcher Ralph P. Schneider, from the Telomeres and Telomerase Group led by María A. Blasco, publishes this week an article in Nature Communications on the discovery of a new gene called TRF1 that is essential for nuclear reprogramming. It is also known that TRF1 is indispensable for protecting telomeres, the ends of chromosomes. …